RxDoctor Payments Data

Aaron Adaoag, MD

Family Medicine · Las Vegas, NVNPI 1609834852

Payments from drug & device makers

$7,096in general payments, 2019–2025

Across 255 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Kowa Pharmaceuticals America, Inc.$1K
  • Amgen$728
  • Novo Nordisk$407
  • Lilly USA, LLC$356
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$1,20017%
  • Food & beverage$5,89683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,096 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$214,637
Medicare patients
85
Services billed
3,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$28,126
OzempicSemaglutide20$27,747
MounjaroTirzepatide13$23,555
FarxigaDapagliflozin Propanediol20$15,268
Atorvastatin Calcium183$2,099
Ezetimibe49$1,081
Rosuvastatin Calcium26$594
Fenofibrate13$533
Amlodipine Besylate49$486
Metformin Hcl71$442
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$304
Alendronate Sodium24$282
Losartan Potassium51$257
Lisinopril65$243
Albuterol Sulfate HfaAlbuterol Sulfate13$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$317$28,12623 claims
Novo NordiskOzempic$407$27,74720 claims
Lilly USA, LLCMounjaro$356$23,55513 claims
AstraZenecaFarxiga$1,651$15,26820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →